Skip to Content

Combination of abemaciclib and trastuzumab +/- fulvestrant improved OS in women with HR+, HER2+ advanced breast cancer  

The combination of abemaciclib and trastuzumab improved survival rates in women with HR+, HER2+ advanced breast cancer compared to chemotherapy plus trastuzumab, with a manageable safety profile.

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top